secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001730463-24-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns
--------------------------------------------------------------------------------

- Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.
- In Feb 2024, closed BioNTech collaboration ($250M upfront) and $350M ADS offering for $600M gross proceeds to fund obe-cel launch.
- BLA for obe-cel in r/r adult B-ALL submitted to FDA; PDUFA target action date Nov 16, 2024; MAA submitted to EMA.
- CDO Dr. Edgar Braendle resigns effective March 2024; will consult. Chris Williams promoted to CBO, Alex Driggs to SVP Legal.
- Obe-cel Phase 1 SLE trial open for enrollment; initial data expected late 2024; Nucleus manufacturing facility obtained MIA for commercial supply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/0001730463-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/autl-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer